Abstract
Hypocretins/orexins are rapidly emerging as functionally important neurotransmitters. Two related neuropeptides (Hcrt-1/OXA, Hcrt-2/OXB) encoded by the same precursor gene and two G-protein coupled receptors (Hcrtr1/OXR1, Hcrtr2/OXR2) are currently known. Hypocretin-containing cells are discretely localized within the perifornical hypothalamus but have widespread projections, with generally excitatory postsynaptic effects. Dense excitatory projections to all monoaminergic cell groups have been reported. A major emerging function for this system is likely to be the regulation of sleep. Alterations in hypocretin neurotransmission causes the sleep disorder narcolepsy in mice, dogs and humans. Effects on appetite, neuroendocrine and energy metabolism regulation are also suggested by other studies. Hypocretins are uniquely positioned to link sleep, appetite and neuroendocrine control, three behaviors of major importance in psychiatry. The potential role of this system in regulating the sleep cycle, modulating wakefulness at selected circadian times and in mediating the deleterious effects of sleep deprivation is discussed.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Abrahamson EE, Leak RK, Moore RY . (2001): The suprachiasmatic nucleus projects to posterior hypothalamic arousal systems. Neuroreport 12: 435–440
Baker TL, Dement WC . (1985): Canine narcolepsy-cataplexy syndrome: evidence for an inherited monoaminergic-cholinergic imbalance. In DJ McGinty, R Drucker-Colin, A Morisson, PL Parmengiani (eds), Brain mechanisms of sleep. New York, Raven Press, 199–233.
Bernasconi R, Mathivet P, Bischoff S, Marescaux C . (1999): Gamma-hydroxybutyric acid: an endogenous neuromodulator with abuse potential? Trends Pharmacol Sci 20: 135–141
Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C, Richardson JA, Williams SC, Xiong Y, Kisanuki Y, Fitch TE, Nakazato M, Hammer RE, Saper CB, Yanagisawa M . (1999): Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98: 437–451
Dantz B, Edgar DM, Dement WC . (1994): Circadian rhythms in narcolepsy: studies on a 90 minute day. Electroencephalogr Clin Neurophysiol 90: 24–35
de Lecea L, Kilduff TS, Peyron C, Gao X-B, Foye PE, Danielson PE, Fukuhara C, Battenberg ELF, Gautvik VT, Barlett FS, Frankel WN, van den Pol AN, Bloom FE, Gautvik M, Sutcliffe JG . (1998): The hypocretins: Hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA 95: 322–327
Edgar DM, Dement WC, Fuller CA . (1993): Effect of SCN lesions on sleep in squirrel monkeys: evidence for opponent processes in sleep-wake regulation. J Neurosci 13: 1065–1079
Estabrooke IV, McCarthy MT, Ko E, Chou TC, Chemelli RM, Yanagisawa M, Saper CB, Scammell TE . (2001): Fos expression in orexin neurons varies with behavioral state. J Neurosci 21: 1656–1662
Fujiki N, Yoshida Y, Ripley B, Honda K, Mignot E, Nishino S . (2001a): Changes in CSF hypocretin-1 (orexin A) levels in rats across 24 hours and in response to food deprivation. Neuroreport 12: 993–997
Fujiki N, Yoshida Y, Ripley B, Mignot E, Nishino S . (2001b): Effect of systemic and central administration of hypocretin-1 in narcoleptic (hcrtr2 mutated) and control dogs. Sleep 24 (suppl):A96–A97
Gillin JC . (1983): The sleep therapies of depression. Prog Neuropsychopharmacol Biol Psychiatry 7: 351–364
Hagan JJ, Leslie RA, Patel S, Evans ML, Wattam TA, Holmes S, Benham CD, Taylor SG, Routledge C, Hemmati P, Munton RP, Ashmeade TE, Shah AS, Hatcher JP, Hatcher PD, Jones DN, Smith MI, Piper DC, Hunter AJ, Porter RA, Upton N . (1999): Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc Natl Acad Sci USA 96: 10911–10916
Hara J, Beuckmann CT, Nambu T, Willie JT, Chemelli RM, Sinton CM, Sugiyama F, Yagami K, Goto K, Yanagisawa M, Sakurai T . (2001): Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 30: 345–354
Higushi T, Takahashi Y, Takahashi K, Nimi Y, Miyasita A . (1979): Twenty-four hour secretatory patterns of growth hormone, prolactive, and cortisol in narcolepsy. J Clin Endocrinol Metabolism 49: 197–204
Hungs M, Mignot E . (2001): Hypocretin/orexin, sleep and narcolepsy. Bioessays 23: 397–408
Kilduff TS, Peyron C . (2000): The hypocretin/orexin ligand-receptor system: implications for sleep and sleep disorders. Trends Neurosci 23: 359–365
Kisanuki YY, Chemelli RM, Sinton CM, Williams SC, Richardson JA, Hammer RE, Yanagisawa M . (2000): The role of orexin receptor Type-1 (OX1R) in the regulation of sleep. Sleep 23(Suppl. 2):A91
Lin L, Faraco J, Li R, Kadotani H, Rogers W, Lin X, Qiu X, de Jong PJ, Nishino S, Mignot E . (1999): The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98: 365–376
Lubkin M, Stricker-Krongrad A . (1998): Independent feeding and metabolic actions of orexins in mice. Biochem Biophys Res Commun 253: 241–245
McCarley RW, Massaquoi SG . (1992): Neurobiological structure of the revised limit cycle reciprocal interaction model of REM cycle control. J Sleep Res 1: 132–137
Marcus JN, Aschkenasi CJ, Lee CE, Chemelli RM, Saper CB, Yanagisawa M, Elmquist JK . (2001): Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol 435: 6–25
Mignot E, Renaud A, Nishino S, Arrigoni J, Guilleminault C, Dement WC . (1993a): Canine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using monoamine selective uptake inhibitors and release enhancers. Psychopharmacology 113: 76–82
Mignot E, Nishino S, Sharp LH, Arrigoni J, Siegel JM, Reid MS, Edgar DM, Ciaranello RD, Dement WC . (1993b): Heterozygosity at the canarc-1 locus can confer susceptibility for narcolepsy: induction of cataplexy in heterozygous asymptomatic dogs after administration of a combination of drugs acting on monoaminergic and cholinergic systems. J Neurosci 13: 1057–1064
Mignot E . (1998): Genetic and familial aspects of narcolepsy. Neurology 50(Suppl 1):S16–S22
Mignot E, Lin L, Rogers W, Honda Y, Qiu X, Lin X, Okun M, Hohjoh H, Miki T, Hsu S, Leffell M, Grumet F, Fernandez-Vina M, Honda M, Risch N . (2001): Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Am J Hum Genet 68: 686–699
Mignot E . (2001): A hundred years of narcolepsy research. Arch Ital Biol 139: 207–220
Miller JD, Faull KF, Bowersox SS, Dement WC . (1990): CNS monoamines and their metabolites in canine narcolepsy: a replication study. Brain Res 509: 169–171
Nakamura T, Uramura K, Nambu T, Yada T, Goto K, Yanagisawa M, Sakurai T . (2000): Orexin-induced hyperlocomotion and stereotypy are mediated by the dopaminergic system. Brain Res 873: 181–187
Nishino S, Mignot E . (1997): Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol 52: 27–78
Nishino S, Mao J, Sampathkumaran R, Shelton J, Mignot E . (1998): Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants. Sleep Res Online 1: 49–61
Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E . (2000): Hypocretin (orexin) deficiency in human narcolepsy. Lancet 355: 39–40
Nishino S, Honda K, Fujuki N, Wurtz SW, Chang M, Sakurai E, Kato M, Watanabe T, Mignot E, Yanai . (2001): The role of histamine in a hypocretin (orexin) deficient sleep disorder narcolepsy. Sleep 24(suppl): A23–A24
Overeem S, Mignot E, Van Djik G, Lammers . (2001): Narcolepsy: Clinical features, new pathophysiologic insight and future perspectives. J Clin Neurophysiology 18: 78–105
Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, Charnay Y, Nevsimalova S, Aldrich M, Reynolds D, Albin R, Li R, Hungs M, Pedrazzoli M, Padigaru M, Kucherlapati M, Fan J, Maki R, Lammers GJ, Bouras C, Kucherlapati R, Nishino S, Mignot E . (2000): A mutation in early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nature Med 6: 991–997
Rechtschaffen A, Bergmann BM . (1995): Sleep deprivation in the rat by the disk-over-water method. Behav Brain Res 69: 55–63.
Ripley B, Fujiki N, Okura M, Mignot E, Nishino S . (2001a): Hypocretin Levels in Sporadic and Familial Canine narcolepsy. Neurobiol Dis 8: 525–534
Ripley B, Benson KL, Zarcone VP, Mignot E, Nishino S . (2001b): CSF hypocretin-1 levels in schizophrenics and controls: relationship to sleep architecture. Sleep 24(suppl):A117
Rodgers RJ, Halford JC, Nunes de Souza RL, Canto de Souza AL, Piper DC, Arch JR, Upton N, Porter RA, Johns A, Blundell JE . (2001): SB-334867, a selective orexin-1 receptor antagonist, enhances behavioral satiety and blocks the hyperphagic effect of orexin-A in rats. Eur J Neurosci 13: 1444–1452
Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, Williams SC, Richardson JA, Kozlowski GP, Wilson S, Arch JR, Buckingham RE, Haynes AC, Carr SA, Annan RS, McNulty DE, Liu WS, Terrett JA, Elshourbagy NA, Bergsma DJ, Yanagisawa M . (1998): Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92: 573–585
Samson WK, Goswell B, Chang JK, Resch ZT, Murphy TC . (1999): Cardiovascular regulatory actions of the hypocretins in the brain. Brain Res 831: 248–253
Shirasaka T, Nakazato M, Matsukura S, Takasaki M, Kannan H . (1999): Sympathetic and cardiovascular actions of orexins in conscious rats. Am J Physiol 277: R1780–R1785
Schuld A, Hebebrand J, Geller F, Pollmacher T . (2000): Increased body-mass index in patients with narcolepsy. Lancet 355: 1274–1275
Sutcliffe JG, de Lecea L . (2000): The hypocretins: excitatory neuromodulatory peptides for multiple homeostatic systems, including sleep and feeding. J Neurosci Res 62: 161–168.
Thannickal TC, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, Aldrich M, Cornford M, Siegel JM . (2000): Reduced number of hypocretin neurons in human narcolepsy. Neuron 27: 469–474
Tokita S, Chemelli RM, Willie WT, Yanagisawa M . (2001): Behavioral characterization of orexin-2 receptor knockout mice. Sleep 24(suppl): A21.
Willie JT, Chemelli RM, Sinton CM, Yanagisawa M . (2001): To eat or to sleep? orexin in the regulation of feeding and wakefulness. Annu Rev Neurosci 24: 429–458
Wisor JP, Nishino S, Sora I, Uhl GH, Mignot E, Edgar DM . (2001): Dopaminergic role in stimulant-induced wakefulness. J Neurosci 21: 1787–1794
Yoshida Y, Fujuki N, Nakajima T, Ripley B, Matsummara H, Yonega H, Mignot E, Nishino S . (2002): Fluctuation of extracellular hypocretin-1 (orexin-A) levels in the rat in relation to the light dark cycle and sleep/wake activities. Eur J Neurosci (in press).
Acknowledgements
This work was supported by NIH NS23724, NS33797, and HL59601 [E.M.]. Thank you to the entire staff of the Center for Narcolepsy for scientific contributions.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mignot, E. A Commentary on the Neurobiology of the Hypocretin/Orexin System. Neuropsychopharmacol 25 (Suppl 1), S5–S13 (2001). https://doi.org/10.1016/S0893-133X(01)00316-5
Issue date:
DOI: https://doi.org/10.1016/S0893-133X(01)00316-5
Keywords
This article is cited by
-
Brain-based gene expression of putative risk genes for anorexia nervosa
Molecular Psychiatry (2023)
-
Predicting gene ontology annotations of orphan GWAS genes using protein-protein interactions
Algorithms for Molecular Biology (2014)
-
Inhibition of orexin-1/hypocretin-1 receptors inhibits yohimbine-induced reinstatement of ethanol and sucrose seeking in Long–Evans rats
Psychopharmacology (2008)
-
Centrally administered orexin A increases motivation for sweet pellets in rats
Psychopharmacology (2005)
